A detailed history of First Horizon Advisors, Inc. transactions in United Therapeutics Corp stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 65 shares of UTHR stock, worth $20,597. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65
Previous 57 14.04%
Holding current value
$20,597
Previous $12,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 26, 2024

BUY
$210.76 - $249.51 $1,686 - $1,996
8 Added 14.04%
65 $14,000
Q4 2023

Feb 06, 2024

BUY
$214.88 - $256.94 $4,082 - $4,881
19 Added 50.0%
57 $12,000
Q3 2023

Oct 27, 2023

BUY
$211.82 - $248.24 $1,482 - $1,737
7 Added 22.58%
38 $8,000
Q2 2023

Aug 03, 2023

BUY
$205.19 - $232.99 $5,540 - $6,290
27 Added 675.0%
31 $6,000
Q3 2022

Nov 09, 2022

SELL
$203.3 - $244.17 $1,219 - $1,465
-6 Reduced 60.0%
4 $0
Q2 2022

Aug 02, 2022

BUY
$174.81 - $241.14 $1,398 - $1,929
8 Added 400.0%
10 $2,000
Q1 2022

May 10, 2022

SELL
$166.16 - $213.96 $332 - $427
-2 Reduced 50.0%
2 $0
Q3 2021

Nov 15, 2021

SELL
$179.86 - $214.88 $3,237 - $3,867
-18 Reduced 81.82%
4 $0
Q3 2021

Nov 09, 2021

BUY
$179.86 - $214.88 $3,956 - $4,727
22 New
22 $4,000
Q3 2020

Nov 12, 2020

SELL
$99.9 - $121.13 $13,186 - $15,989
-132 Closed
0 $0
Q1 2020

May 05, 2020

SELL
$79.39 - $115.35 $952 - $1,384
-12 Reduced 8.33%
132 $12,000
Q4 2019

Jan 07, 2020

BUY
$78.31 - $95.34 $939 - $1,144
12 Added 9.09%
144 $12,000
Q3 2018

Nov 05, 2018

SELL
$113.81 - $129.46 $15,591 - $17,736
-137 Reduced 50.93%
132 $0
Q2 2018

Aug 07, 2018

BUY
$101.14 - $118.31 $4,753 - $5,560
47 Added 21.17%
269 $0
Q2 2017

Aug 14, 2017

BUY
N/A
222
222 $0

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $14.4B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.